patritumab
Daiichi Sankyo,Amgen
['bcsm', 'rux,(-crux),(-trux)', 'patritumab', 'breast']
treatment with patritumab deruxtecan produced a tolerable safety profile and improved clinical activity among patients with heavily pretreated estrogen receptor-positive and triple-negative metastatic breast cancers. #bcsm #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.